On 9 August, STAT News reported that the US health secretary recently declared monkeypox as a public health emergency, paving the way for emergency use authorisations of additional vaccines or vaccine regimens to fight the disease.
The same day, Food and Drug Administration (“FDA”) Commissioner Robert Califf said that the US government is seriously considering stretching the very limited supply of Bavarian Nordic’s Jynneos vaccine – the only vaccine licensed against monkeypox in the US – by changing the way it is given. Instead of giving a full dose subcutaneously (into the fat layer under the skin), a lower dose of the vaccine could be given intradermally (injecting the vaccine within the skin). The FDA may soon issue an emergency authorisation for Jynneos to be administered in this way. Will low-dose vaccination stretch the monkeypox vaccine supply, or backfire? STAT, 9 August 2022
But this strategy could also backfire, STAT News noted: “If there is a risk to effectiveness, it may be better to focus the available full doses of vaccine on individuals at highest risk – men who have sex with multiple male partners.”...<<<Read More>>>...
